Colorectal cancer - treatment after prior fluoropyrimidine-based combination chemotherapy

Active Ingredient: Nivolumab

Indication for Nivolumab

Population group: only adults (18 years old or older)

Therapeutic intent: Curative procedure

Nivolumab in combination with ipilimumab is indicated for the treatment of adult patients with mismatch repair deficient or microsatellite instability-high colorectal cancer in the setting of treatment of metastatic colorectal cancer after prior fluoropyrimidine-based combination chemotherapy.

For this indication, competent medicine agencies globally authorize below treatments:

3 mg/kg every 3 weeks for the first 4 doses, followed by 240 mg every 2 weeks

For:

Dosage regimens

Intravenous, 3 milligrams nivolumab per kilogram of body weight, once every 3 weeks, 4 doses in total, over the duration of 12 weeks. Afterwards, intravenous, 240 milligrams nivolumab, once every 2 weeks.

Detailed description

The recommended dose in patients who received prior fluoropyrimidine-based combination chemotherapy for dMMR or MSI-H CRC is 3 mg/kg nivolumab in combination with 1 mg/kg ipilimumab administered intravenously every 3 weeks for the first 4 doses, followed by nivolumab monotherapy administered intravenously 240 mg every 2 weeks. For the monotherapy phase, the first dose of nivolumab should be administered 3 weeks after the last dose of the combination of nivolumab and ipilimumab.

Active ingredient

Nivolumab
Nivolumab is a human immunoglobulin G4 (IgG4) monoclonal antibody (HuMAb), which binds to the programmed death-1 (PD-1) receptor and blocks its interaction with PD-L1 and PD-L2. Nivolumab potentiates T-cell responses, including anti-tumour responses, through blockade of PD-1 binding to PD-L1 and PD-L2 ligands. In syngeneic mouse models, blocking PD-1 activity resulted in decreased tumour growth. Read more about Nivolumab

Related medicines

Summary of Product Characteristics (SPC) 2025: OPDIVO Concentrate for solution for infusion

Develop a tailored medication plan for your case, considering factors such as age, gender, and health history

Ask the Reasoner

Liability Disclaimer : RxReasoner has utilized reasonable care in providing content and services that are accurate, complete and up to date. However, RxReasoner does not accept any responsibility or liability about it. The content and services of RxReasoner are for informational purposes only and they are not intended to be a substitute for the knowledge, expertise, skill, and judgment of physicians, pharmacists, nurses, or other healthcare professionals involved in patient care. RxReasoner offers no medical advice. Users are responsible for the use of the provided content. A shown indication or treatment should not be construed to indicate that the medication is safe, appropriate, or effective in any given patient or under any particular circumstances. The absence of an indication or treatment should not roule out the existence of other appropriate medications. Always seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition or medicament. RxReasoner is not liable for any damages allegedly sustained arising out of the use of its content and services.